author-photo

Carla Visseren-Grul

Eli Lilly and Company

96

Papers

2905

Citations

Citation Trend

Filter By

Papers (96) Sort By

JournalConferenceOthers

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Ramucirumab Plus Erlotinib vs. Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated Non-small Cell Lung Cancer: RELAY Japanese Subset

2021
Show All
- Source
- Cite
- Save
Citations (0)
1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

2021 Cancer treatment and research
Show All
- Source
- Cite
- Save
Citations (1)
MO29-5 RELAY+: Exploratory study of RAM+GEF in untreated patients with EGFR M+ NSCLC: Updates on efficacy, safety and biomarker

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreated EGFR mutation-positive metastatic NSCLC: Next generation sequencing (NGS) results

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
1298P RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号